Daiichi Sankyo, Inc. Release: First Clinical Trial To Demonstrate Colesevelam HCl Plus Stable Oral Antidiabetic Medication Improves Glycemic Control In Patients With Type 2 Diabetes

PARSIPPANY, NJ -- (MARKET WIRE) -- 06/10/2006 -- The first data to demonstrate the effect of WelChol® (colesevelam hydrochloride) on glucose lowering was presented today at The American Diabetes Association’s (ADA) 66th Annual Scientific Sessions in Washington, DC. WelChol treatment resulted in a mean 0.5% reduction in A1C versus placebo (p=0.007). Moreover, in patients with A1C greater than or equal to 8.0%, WelChol lowered A1C by 1.0% compared to placebo (p=0.002).